“AstraZeneca has agreed to limit access to its lung cancer drug Iressa after the FDA concluded that clinical testing had been unable to prove the treatment’s survival benefit.

“Based on the FDA’s assessment of currently data and the availability of other treatment options in the US that do prolong life, AstraZeneca said that it would revise Iressa’s label to restrict the drug’s use to patients who have previously taken and benefited from the therapy.”

Read more at FDA endorses restrictions on Iressa

Recent Entries

• Sigma Pharmaceuticals year profit rises 27 pct
• South African citizens cheap drug guinea pigs
• Two drugs test victims face a year in coma
• Can drug companies improve their reputation?
• Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
• Pfizer’s Forecast Disappoints
• Pharmaceutical RFID Adoption Stalls
• Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
• GlaxoSmithKline unveils best results since merger
• Pfizer Sues Teva, Sandoz Over Zithromax

This entry was posted on Wednesday, June 22nd, 2005 at 2:46 am and is filed under General. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.